Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Year 2 Collaborative Project - UCSF and Battelle PNWD

Year 2 Collaborative Project - UCSF and Battelle PNWD

238

No involved investigator sites defined.

amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1 and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor , tissue necrosis factor , urokinase plasminogen activator, vascular endothelial growth factor
Proteomics
Breast and Gynecologic Cancers Research

To evaluate the effects of receptor status on circulating biomarker levels.

To analyze plasma levels of 24 proteins in 60 samples from women with either benign breast disease, or Her+ or ER+ cancers.
ELISA microarray

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 04/26/2017

A new funding opportunity associated with the Beau Biden Cancer Moonshot Initiative, Integration and Validation of Emerging Technologies to Accelerate Cancer Research, has been released and is due May 10, 2017. Click here for more information.

Announcement 03/14/2017

Thank you to everyone who made the March 2017 EDRN Steering Committee Meeting a success. The next EDRN Steering Committee Meeting will be on September 12-14, 2017, in Seattle, WA.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.